Search filters

List of works by Charles Craig

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

scientific article

Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis

scientific article

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.

scientific article

Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

scientific article published in July 2001

Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients

article

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study ⬇️

scientific article published on May 1, 2010

Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).

scientific article published in April 2006

Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial

scientific article published on September 2014

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.

scientific article published on 2 November 2014

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy

scientific article published on 01 September 1998

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc

scientific article published on 01 January 2021

In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV

scientific article

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials

scientific article published on 01 January 2019

Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

article

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy

scientific article

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

scientific article published on 5 February 2016

Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.

scientific article published on 7 October 2017

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study.

scientific article

Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen

scientific article published on 01 January 2006

The development of resistance of HIV-1 to zalcitabine

scientific article published on 01 March 1997

The maraviroc expanded access program - safety and efficacy data from an open-label study

scientific article

Paulina is supported by:

About Paulina

Help